Financials Carmell Corporation

Equities

CTCX

US1429221039

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 31/05/2024 BST 5-day change 1st Jan Change
2.49 USD +1.63% Intraday chart for Carmell Corporation -3.11% -34.65%

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 - - 87.94
Enterprise Value (EV) 1 - - 87.17
P/E ratio -32.8 x -29.5 x -2.6 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -17 x
EV / FCF - - -2,794,701 x
FCF Yield - - -0%
Price to Book -12 x -3.81 x 3.55 x
Nbr of stocks (in thousands) - - 23,082
Reference price 2 9.620 9.917 3.810
Announcement Date 14/02/23 05/05/23 01/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales - - -
EBITDA 1 -1.846 -5.413 -5.12
EBIT 1 -1.94 -5.508 -5.217
Operating Margin - - -
Earnings before Tax (EBT) 1 -6.479 -9.051 -16.21
Net income 1 -6.479 -9.051 -15.45
Net margin - - -
EPS 2 -0.2933 -0.3366 -1.463
Free Cash Flow - -5.872 -31.19
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 14/02/23 05/05/23 01/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 9.67 3.61 -
Net Cash position 1 - - 0.78
Leverage (Debt/EBITDA) -5.24 x -0.6663 x -
Free Cash Flow - -5.87 -31.2
ROE (net income / shareholders' equity) - 83.7% -176%
ROA (Net income/ Total Assets) - -208% -9.93%
Assets 1 - 4.346 155.6
Book Value Per Share 2 -0.8000 -2.600 1.070
Cash Flow per Share 2 0 0.0100 0.1300
Capex 1 0.01 0.01 0.03
Capex / Sales - - -
Announcement Date 14/02/23 05/05/23 01/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. CTCX Stock
  4. Financials Carmell Corporation